The efficacy of AB103 was tested in several models of bacterial infections, including: Gram-positive infections (S. pyogenes and S. pneumoniae), Gram-negative infections (E. coli) and mixed infections (intra-abdominal polymicrobial infection). It was tested either as a stand- alone treatment (in S. pyogenes) or in combination with antibiotics in the other infections. AB103 demonstrated increased survival, reduction of systemic and local inflammation and reduced bacterial burden, without compromising cellular and humoral immunity
A. Efficacy in gram positive bacterial infection (Group A. Streptococcus pyogenes; GAS). Administration of a single dose of AB103 increased survival, when animals are treated either early or late post infection.
J Infect Dis. 2013 Jun 15;207(12):1869-77
Reduction necrosis at the infection site
AB103 given post infection improve muscle inﬂammation and prevents necrosis
B. Efficacy in Gram-negative bacterial infection: AB103 protects mice from lethal E. coli peritonitis following its administration with antibiotics at 4 h after E. coli challenge. *, p‹0.01 vs. PBS or antibiotics alone.